Ataxia-Telangiectasia
Oct 02, 2026
AQNEURSA Leads a New Chapter in Ataxia-Telangiectasia as the Pipeline Faces Its Next Test
Summary Ataxia-telangiectasia is a rare, progressive genetic disorder affecting an estimated 1 in 40,000–100,000 people worldwide. AQNEURSA received FDA approval on September 18, 2026, becoming the first and only approved treatment for ataxia in patients with ataxia-telangiectasia and marking the first...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
